Kim JH, et al. - In this retrospective analysis of 179 patients (179 eyes) diagnosed with type 3 neovascularization and treated with three monthly anti-vascular endothelial growth factor (VEGF) injections, researchers assessed long-term incidence and timing of reactivation. Follow-up of patients was performed following the initial treatment until the first reactivation, and no further injection was given during this period. Participants were followed-up for a mean duration of 37.5 ± 18.8 months. Nearly all reactivation occurred within 15 months of the third anti-VEGF injection, highlighting the requirement of close follow-up and detailed assessments during this period. More frequent monitoring during this early period was recommended in female patients with thick choroid.